AtaiBeckley (ATAI) Director Fischer Laurent Disposes 430,968 Derivative Shares

What Happened
Fischer Laurent, a director of AtaiBeckley Inc. (ATAI), recorded dispositions of derivative awards (stock options/rights) on September 11, 2026. The filing shows three dispositions to the issuer of 206,000; 103,000; and 121,968 derivative units, totaling 430,968. No per-share sale price is reported on the Form 4 because, under the Merger, each option was cancelled and converted into (a) a cash payment equal to the number of shares times the excess of $6.75 over the option exercise price and (b) one contingent value right (CVR) per share (each CVR may pay up to $2.50 on achievement of specified milestones), less applicable tax withholding. These actions resulted from the company’s merger with Eli Lilly (Merger effective 2026-09-11), not an open-market sale.

Key Details

• Transaction date: 2026-09-11 (Merger effective date)
• Transaction type/code: Disposition to issuer (D); derivative instruments cancelled/converted (not an open-market sale)
• Shares/units disposed: 206,000; 103,000; 121,968 — total 430,968
• Price reported on Form 4: N/A (cash consideration is determined by formula described in footnote; aggregate cash not specified on this filing)
• Consideration received: Cash (formulaic amount dependent on each option’s exercise price) and one CVR per share (up to $2.50 per CVR upon milestone achievement)
• Shares/ownership after transaction: Not disclosed in the provided Form 4
• Footnotes of note: F1 — merger with Eli Lilly made the company a wholly owned subsidiary (effective 9/11/2026). F2 — outstanding options were cancelled and converted into cash plus CVRs (details above).
• Timeliness: Form lists the Period of Report as 2026-09-11 and was filed 2026-09-11, indicating the filing appears timely.

Context

• These are derivative cancellations related to a corporate merger (common in M&A): outstanding options were cashed out/converted rather than sold on the open market.
• CVRs are contingent payments tied to future clinical/regulatory milestones; their payout is uncertain and depends on achievement of those milestones.
• This filing documents a merger-driven disposition of derivative awards and should not be read as a routine insider market sale or a direct signal of personal trading sentiment.